Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$133.05 USD
+0.53 (0.40%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $133.01 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADUS 133.05 +0.53(0.40%)
Will ADUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADUS
Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
ADUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Addus HomeCare (ADUS) Reports Q2 Earnings: What Key Metrics Have to Say
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
ADUS vs. CHE: Which Stock Is the Better Value Option?
Other News for ADUS
Small cap stocks that could perform best during ‘downturns’ – BofA
Addus HomeCare management to meet with Oppenheimer
Addus HomeCare management to meet with Oppenheimer
Insider Sale: EVP/CFO Brian Poff Sells 6,839 Shares of Addus HomeCare Corp (ADUS)
Insider Sale: EVP / Chief Legal Officer Sean Gaffney Sells Shares of Addus HomeCare Corp (ADUS)